|A010-214||SARS-CoV-2 S protein RBD||10 μg||60 μg|
|A011-214||Biotinylated Human ACE2||10 μg||10 μg|
|A003-214||Streptavidin-HRP||10 μg||10 μg|
|AC2-NA005||SARS-CoV-2 Inhibitor (Human ACE2)||20 μg||50 μg|
Upon receipt, please store all items at -20℃ to -70℃. After reconstitution, the stock solution should be kept at -70℃.
It is recommended not to freeze thaw more than 3 times.
This product is stable after storage at: Room temperature (RT) for 1 month in lyophilized state; -20℃ to -70℃ for 1 year in lyophilized state; -70℃ for 6 months under sterile conditions after reconstitution
Your experiment will include 4 simple steps:
a) Coat the plate with SARS-CoV-2 S protein RBD.
b) Add 50ul biotinylated human ACE2 to coated plate.
c) Add the reference or your molecule of interest.
d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.
Finally, the ability of your compound to inhibit S protein RBD: ACE2 binding will be determined by comparing OD readings among different experimental groups.
Binding of Biotinylated Human ACE2 To Immobilized SARS-CoV-2 S protein RBD In A Functional ELISA Assay.
Immobilized 2019-CoV-2 S protein RBD at 0.5 μg/mL (100 μL/well) can bind human ACE2-Biotin with a linear range of 0.001- 0.06 μg/mL when detected by Streptavidin-HRP. Background was subtracted from data points before curve fitting.
Inhibition of Human ACE2 [Biotinylated] :SARS-CoV-2 S protein RBD Binding by SARS-CoV-2 inhibitor.
Serial dilutions of SARS-CoV-2 inhibitor (Cat. No. AC2-NA005) (1:2 serial dilutions, from 20 μg/mL to 0.039 μg/mL (180 nM to 0.35 nM)) was added into Biotinylated ACE2: SARS-CoV-2 S protein RBD binding reactions. The assay was performed according to the above described protocol. Background was subtracted from data points prior to log transformation and curve fitting.
Authors: Balkrishna, Acharya et al.
Journal: Drug Des Devel Ther 2021
Price(USD) : $600.00
Price(USD) : $2150.00
Price(USD) : $100.00
ACROBiosystems has developed an exclusive immune checkpoint protein collection， The consistency and excellent performance of our proteins are confirmed by a variety of assays.
ACROBiosystems has developed a series of homogeneous CD3 proteins with good bioactivity. They are verified as 1:1 heterodimers by nonreductive electrophoresis and MALS as well.
ACROBiosystems has developed a series of products with different species and tags for a variety of hot targets. It is suitable for immune, antibody screening, SPR, cell activity detection and other experiments, and all SPR&BLI protocols are available for free.
We also supply difficult-to-express proteins such as BCMA, CD19, ROR1, and EGFRVIII.
This web search service is supported by Google Inc.